Hospira will acquire the generic injectable finished-dosage form pharmaceuticals business of Orchid Chemicals & Pharmaceuticals for approximately $400 million. The acquisition includes Orchid’s beta-lactam antibiotics manufacturing complex (comprising cephalosporin, penicillin and carbapenem facilities) and R&D facility at Irungattukottai, Chennai, as well as its generic injectable product portfolio and pipeline. Beta-lactam antibiotics represent a class of drugs with a wide spe...